Structure-guided design and development of cyclin-dependent kinase 4/6 inhibitors: A review on therapeutic implications
Source : https://www.sciencedirect.com/science/article/abs/pii/S0141813022015884?via=ihub
CDK4/6 is directly involved in cancer signaling and is considered an attractive drug target. * This review highlights biological roles, structural features and potential inhibitors of CDK4/6 in detail. *...
Relevance: Here, we discuss the roles of CDK6 in cancer along with the present status of CDK4/6 inhibitors in cancer therapy. We further discussed, how structural features of CDK4/6 could be implicated in the design and development of potential anti-cancer agents. In addition, the therapeutic potential and limitations of available CDK4/6...
Final overall survival analysis of KEYNOTE-355, demonstrating overall survival benefit to the addition of pembrolizumab to chemotherapy in the first line setting for metastatic TNBC.
-
Breast Cancer Connect4yr#:~:text=The%20final%20overall%20survival%20results,least%2010%20and%20who%20received
Risk factors of non-sentinel lymph node metastasis in 443 breast cancer patients with sentinel lymph node-positive - PubMed
Source : https://pubmed.ncbi.nlm.nih.gov/35866760/
Axillary lymph node dissection is the standard surgical procedure for breast cancer patients with sentinel lymph node (SLN) positive. In clinical practice, axillary lymph node dissection may be an unnecessary...
Conclusion: For clinical early breast cancer with positive SLN, primary tumor size T > 2 cm,the positive number of SLNs ≥ 3, the ratio of positive SLNs ≥ 50%, and SLN macrometastases could predict NSLN metastasis well, and guide surgery to avoid overtreatment.
Molecular vulnerabilities and therapeutic resistance in hormone receptor positive and HER2 dependent breast cancer tumours
Source : https://cdrjournal.com/article/view/4769
Human epidermal growth factor receptor 2 ( HER2), a gene frequently implicated in breast cancers and a variety of other tumour types, results in a growth factor receptor, which, when...
Conclusion/Relevance: This review focuses on the recent resistance mechanisms identified and potential therapeutic targets for conventional and combination endocrine therapies with CDK4/6 inhibitors by various breast cancer clinical trials and research groups in HER amplified and/or mutated breast cancer tumour. Activating HER2 alterations, JNK...
Molecular perspective on targeted therapy in breast cancer: a review of current status - Medical Oncology
Source : https://link.springer.com/article/10.1007/s12032-022-01749-1
Breast cancer is categorized at the molecular level according to the status of certain hormone and growth factor receptors, and this classification forms the basis of current diagnosis and treatment....
Conclusion/Relevance: Promising advances have been made in clinical trials investigating the effect of these new treatment modalities and their combinations with existing therapeutic treatments in the treatment of breast cancer. Monoclonal antibodies, tyrosine kinase inhibitors, antibody–drug conjugates, PI3K/Akt/mTOR pathway inhibitors,...